Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03553875 · ClinicalTrials.gov registry record · Phase 3
Memantine for the Treatment of Social Deficits in Youth With Disorders of Impaired Social Interactions
A Phase 3 study, sponsored by Massachusetts General Hospital.
- Terminated
- Registry status
- Phase 3
- Development phase
- 25
- Enrollment target
NCT03553875: Clinical Trial Phase 3 study, sponsored by Massachusetts General Hospital.
NCT03553875 is a Phase 3 study that was terminated before completion, run by Massachusetts General Hospital. The registered enrollment target is 25 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03553875, a Phase 3 study, was terminated before completion, sponsored by Massachusetts General Hospital.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 25 participants
- Enrollment target
Study Summary
This study is a 12-week randomized-controlled trial of memantine hydrochloride (Namenda) for the treatment of social impairment in youth with Non-Verbal Learning Disorder, High-Functioning Autism Spectrum Disorder, and related conditions. Eligible participants will be males and females ages 8-18. This study consists of up to 6 visits to Massachusetts General Hospital.
Interventions
- DRUG Placebo
- DRUG Memantine Hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2018-11-13 |
| Est. Completion | 2025-11-25 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03553875
The ClinicalTrials.gov registry entry for NCT03553875 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03553875 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03553875 about?
NCT03553875 is a clinical study titled "Memantine for the Treatment of Social Deficits in Youth With Disorders of Impaired Social Interactions". This study is a 12-week randomized-controlled trial of memantine hydrochloride (Namenda) for the treatment of social impairment in youth with Non-Verbal Learning Disorder, High-Functioning Autism Spectrum Disorder, and related conditions. Eligible participants will be males and females ages 8-18. T...
What is the current status of trial NCT03553875?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 25 participants. The study started on 2018-11-13. Estimated completion is 2025-11-25.
What interventions are being tested in trial NCT03553875?
The interventions under investigation include: Placebo (DRUG), Memantine Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT03553875?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.